Get started
Author

Simone Leyden

Observed name: S. Leyden
Institution: Cancer Australia
ORCID: 0000-0003-0084-1769
Observed ORCID: 0000-0003-0084-1769
OpenAlex ID: A5026565376
Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines
2020 · Simron Singh, Emily K. Bergsland, et al. · Journal of Thoracic Oncology · 126
Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals
2019 · Simone Leyden, Teodora Kolarova, et al. · International Journal of Cancer · 32
PDF
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results.
2022 · Nick Pavlakis, David Turner Ransom, et al. · Journal of Clinical Oncology · 31
Pivotal phase III COMPOSE trial will compare 177 Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.
2022 · Thorvardur Ragnar Halfdanarson, Diane Lauren Reidy, et al. · Journal of Clinical Oncology · 30
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).
2020 · Nick Pavlakis, David Turner Ransom, et al. · Journal of Clinical Oncology · 25
The Economic Impact on Australian Patients with Neuroendocrine Tumours
2020 · Louisa G. Gordon, Thomas M. Elliott, et al. · Patient · 18
Global challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients
2023 · Sugandha Dureja, Mark McDonnell, et al. · Journal of Neuroendocrinology · 14
PDF
902TiP COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours
2022 · T.R. Halfdanarson, D. Halperin, et al. · Annals of Oncology · 6
PDF
Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention
2019 · Lisa Guccione, Karla Gough, et al. · JMIR Research Protocols · 4
PDF
[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial
2026 · David L. Chan, Katrin Marie Sjoquist, et al. · European Journal of Cancer · 2
1168P Survey of challenges in access to diagnostics and treatment for neuroendocrine tumour (NET) patients (SCAN): Healthcare quality evaluation
2020 · C.V. Bouvier, D. Van Genechten, et al. · Annals of Oncology · 2
The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)
2018 · E. Segelov, E. Bergsland, et al. · Annals of Oncology · 2
COMPOSE: Pivotal Phase III Trial for Well-Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care
2023 · Halfdanarson Thorvardur R, Halperin Daniel M, et al. · Endocrine Abstracts · 1
Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.
2023 · Thorvardur Ragnar Halfdanarson, Jaume Capdevila, et al. · Journal of Clinical Oncology · 1
PDF
Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): The diagnostic process of GEP-NETs in Australia, Canada, China, France, Germany, the United Kingdom, and the United States of America.
2022 · Mark McDonnell, Catherine Bouvier, et al. · Journal of Clinical Oncology · 1
Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN): Awareness of specialized techniques and latest interventions.
2020 · Mark McDonnell, Dirk Van Genechten, et al. · Journal of Clinical Oncology · 1
Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality.
2019 · Simone Leyden, Teodora Kolarova, et al. · Journal of Global Oncology · 1
P1.12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus
2018 · S. Singh, E. Bergsland, et al. · Journal of Thoracic Oncology · 1
Author response for "Global Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor ( NET ) Patients"
2023 · Sugandha Dureja, Mark McDonnell, et al.
Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN) – application of surgery in treatment of SI NETs
2022 · Dirk Van Genechten, Mark McDonnell, et al. · European Journal of Surgical Oncology
The cost of neuroendocrine tumor patient healthcare: Comparison between advanced economies and emerging and developing economies.
2021 · Elyse Gellerman, Catherine Bouvier, et al. · Journal of Clinical Oncology
1113P Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America
2021 · T. Kolarova, M. McDonnell, et al. · Annals of Oncology
PDF
P-92 The neuroendocrine tumor diagnostic process and the role of gastrointestinal specialists
2021 · S. Leyden, M. McDonnell, et al. · Annals of Oncology
PDF
Treatments and ongoing monitoring for patients with neuroendocrine tumors, monitored by medical oncologists: Scan comparative data between advanced economies (AE) and emerging and developing economies (EDE).
2021 · Christine Rodien-Louw, Mark McDonnell, et al. · Journal of Clinical Oncology
Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN) - UK and Ireland vs global diagnosis of NETs
2020 · Catherine Bouvier, Mark McDonnell, et al. · Endocrine Abstracts
Works count: 29
Citation count: 298
H-index: 7
I10-index: 7
Year
Topic
Type